Corticosteroid Injections in Knee Osteoarthritis

Evidence on Disease Progression

The American College of Rheumatology/Arthritis Foundation acknowledges that corticosteroid injections may contribute to cartilage loss, but the guideline panel determined this finding lacked clinical significance because changes in cartilage thickness were not associated with worsening pain, function, or other radiographic features 1, 2, 3.
The VA/DoD guidelines note that providers must consider potential long-term negative effects on bone health, joint structure, and meniscal thickness associated with repeat intra-articular corticosteroid administration, despite recommending corticosteroid injections for persistent knee OA pain 4, 5, 6.

Intra-articular corticosteroid injections are strongly recommended for knee OA by the American College of Rheumatology, with benefits including improved function at 4 and 24 weeks with methylprednisolone 1, 2, 3.
The AAOS found considerable evidence supporting the use of corticosteroid injections, with 19 high-quality and 6 moderate-quality studies demonstrating efficacy 7.
Triamcinolone shows benefit at 6 weeks but not 12 weeks, and effects are time-limited without long-term improvement at 2-year follow-up 4, 5, 6.

Avoid corticosteroid injection for 3 months preceding joint replacement surgery due to theoretical infection risk, though the VA/DoD systematic review found limited data describing elevated risk of deep joint infection 4, 5, 6.
The duration of benefit is typically only 3 months, which may be offset by slower onset of action compared to other treatments 8.

Corticosteroid injections are conditionally recommended over hyaluronic acid preparations, as the evidence for glucocorticoid efficacy is considerably higher quality 1, 2, 3, 9, 10.